Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa.

Remicade (infliximab) - J&J

Bimzelx (bimekizumab-bkzx) - UCB

clindamycin phosphate - Generic mfg.

triamcinolone acetonide - Generic mfg.

moxifloxacin intravenous - Generic mfg.

Humira (adalimumab) - AbbVie

tetracycline - Generic mfg.

Tremfya (guselkumab) - J&J

isotretinoin - Generic mfg.

methotrexate - Generic mfg.

Cosentyx (secukinumab) - Novartis

Invanz (ertapenem) - Merck (MSD)

Opzelura (ruxolitinib cream) - Incyte

Jakafi (ruxolitinib) - Incyte

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

doxycycline - Generic mfg.

rifampicin - Generic mfg.

Rinvoq (upadacitinib) - AbbVie

spironolactone - Generic mfg.

azathioprine - Generic mfg.

acitretin - Generic mfg.

Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa. (PubMed, J Am Acad Dermatol) - Oct 21, 2026 - "These guidelines provide evidence-based recommendations for the management of hidradenitis suppurativa."
Journal • Aesthetic Medicine • Dermatology • Hidradenitis Suppurativa • Immunology • Pain • Tobacco Cessation

http://www.ncbi.nlm.nih.gov/pubmed/42900024

Amit Garg; Amy J McMichael; Christopher John Sayed; Craig N Burkhart; George K Hightower; Ginette Okoye; Haley B Naik; Howa Yeung; Kelly Keeler; Lauren A V Orenstein; Lindsy Frazer-Green; Melanie Plotke; Melissa Shive; Peggy A Wu; Steven Daniel Daveluy

Oct 21, 2026